Mpc1 knockout in hepatocytes improves NAFLD [50], while MPC inhibition with pioglitazone (a TZD), MSCD-0602 (a PPAR-γ-sparing, TZD-like molecule) or liver Mpc2 deletion correlates with improved NASH [63,64]. Here, MPC1 is linked to metabolic dysfunction-associated steatohepatitis.